Sacral neuromodulation (SNM) is increasingly used to treat lower urinary tract symptoms and bowel symptoms refractory to conventional therapy. 1 The US Food and Drug Administration approved the device in 1997, and the device was modified in 2006, which included a 50% reduction in size and an improvement in leads to decrease lead migration. These changes at least partially explain the more than 3.5-fold increase in the number of SNM procedures in the following 5 years.
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The indications for SNM use are growing despite the lack of evidence. Hence, we sought to determine the reintervention rate associated with treatment failures and device malfunctions at 1, 3, and 5 years after surgery. The secondary aim was to evaluate the volume-outcome relationship. (Table) . There were no significant differences between high vs low volume hospitals or surgeons.
Discussion | We found an alarming number of reinterventions, mostly because of device malfunctions, in patients undergoing SNM for all indications. One in 3 patients had some form of reintervention-either revision or removal-within 3 to 5 years of initial device placement, which is in stark contrast to the manufacturer's reported device survival probability of 97.9% over a 3-year period. 5 Almost half of the patients undergoing reintervention needed it within the first year, and hospital and surgeon volume did not influence these results. 
Surgeon
The box indicates the interquartile range; the line, the median; the point, the mean; the error bars, 95% CIs. Our previous study 2 using limited 5% Medicare data reported an 11.3% reintervention rate at 90 days and a 33% rate at 5 years. In a 5-year follow-up study of patients implanted with SNM for overactive bladder, Siegel et al 6 also reported only a 67% therapeutic success rate. We extend these results in, to our knowledge, the first large-scale, all-inclusive statewide study demonstrating high SNM device failure. We found that device malfunction was the second most common indication for early reinterventions and the predominant indication at 5 years. Moreover, our results demonstrate that even in the hands of high-volume surgeons, the invasive surgical reintervention rate remains very high. Limitations include generalizability to the entire US population, despite inclusion of all ages and data from all of New York, with its diverse population and practices. Use of billing codes may introduce some misclassification but is a valid method, particularly for reinterventions.
Conclusions | Sacral neuromodulation is associated with a very high rate of failure, as measured by reinterventions, that occur at alarming rates within 5 years of placement. A device registry is urgently needed in this setting to advise stakeholders and assist future innovations.
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